Objectives: The purpose of this study was to investigate the role and mechanism of circ_0002762 in CC. Design:Silencing circ_0002762 in CC cells and xenograft tumor models to investigate the role of circ_0002762 in CC in vitro and in vivo. Materials and Methods: The relative expression levels of circ_0002762, miR-526b-5p and hexokinase2 (HK2) in CC tissues and cells were detected by real-time quantitative polymerase chain reaction (RT-qPCR) or western blot. Glycolysis-related extracellular acidification rate, glucose production, lactic acid consumption, and ATP levels were measured using the appropriate kits. Cell proliferation was assessed by 5-Ethynyl-2'-deoxyuridine (EdU) and colony formation assay. Cell apoptosis was detected by flow cytometry. The binding relationship between miR-526b-5p and circ_0002762 or HK2 was verified by dual-luciferase reporter assay and RNA pull-down assay. Tumor growth in vivo was detected by xenograft tumor model. Results: The expressions of circ_0002762 and HK2 were up-regulated and miR-526b-5p was down-regulated in CC tissues and cells. Circ_0002762 knockdown inhibited glycolysis and proliferation and promoted apoptosis of CC cells. In addition, miR-526b-5p suppression reversed the inhibition of CC development induced by circ_0002762 silencing. HK2 overexpression eliminated the inhibition of miR-526b-5p on CC progression. Moreover, silencing of circ_0002762 inhibited CC tumor growth in vivo. Limitations:The practical application of Circ_0002762 in clinical needs further investigation. Conclusion: Circ_0002762 knockdown inhibited CC progression by regulating miR-526b-5p/HK2 axis, suggesting that circ_0002762 was a promising therapeutic strategy for CC.

The safety of magnetic resonance imaging (MRI) scans in patients undergoing dual-chamber pacemaker (Medtronic's EnRhythm MRI SureScan IPG (implantable pulse generator) and CapSureFix MRI pacing electrodes) implantation were evaluated. A total of 86 patients undergoing this pacemaker implantation who were admitted to Huanggang Hospital from June 2006 to March 2017 were continuously selected. On average 6.8±2.3 months after the implantation, the first MRI scan was conducted. The mean scan time was 2.2±0.9 and mean duration was 45.6±12.3 min; mean follow-up visit period was 40.5±15.6 months, and after follow-up, all the abnormal symptoms of patients and pacemaker abnormalities after scans were recorded. Causes of receiving MRI scans included neurological diseases (27%), spinal diseases (14%), cancers (26%), joint injuries (25%) and visceral systems (8%). A total of 12 cases (14.0%) showed significant discomfort symptoms, 10 cases (11.6%) showed pacemaker abnormalities, and the incidence rate was 25.6%. Multivariate logistic regression analysis showed that the basic types of cardiovascular diseases, dependence on pacemakers, duration of education, pacing threshold, impedance and MRI scan time were related to the occurrence of adverse scan results (p<0.05). In conclusion, MRI scans show that MRI-compatible dual-chamber pacemaker was relatively safe.

Background Gouty arthritis-causing uric acid is persistently in excess in the form of tophi. The ultimate therapeutic ideal should be to completely eliminate all tophi. So far, clinicians have relied on physical examination and plain radiographs to assess the locations and sizes of Gouty tophi. The dual energy computerized tomography (DECT), magnetic resonance imaging (MRI), 2-fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) each offers a different perspective of gouty tophi. None of the papers have used all four techniques concomitantly, no guidelines are available concerning their applications. Objectives To visualize in a gout patient,using four different imaging techniques,the locations, sizes, compactness of tophi. Methods The feet and knees were imaged by X-ray, MRI, DECT and PET. Results DECT uncovered deposits in unexpected locations. The combination of DECT, MRI and PET showed that tophi were much larger and more inflammatory than clinically suspected. Conclusions The locations and sizes of tophi in chronic gout patients can far exceed those accessible by physical examination and X-ray. These can be critical when making decisions concerning the initiation and aggressiveness of serum uric acid- lowering therapies. References Neogi T. Clinical practice. Gout. N Engl J Med. 2011 Feb 3;364(5):443-52. Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol. 2009 Mar;21(2):124-31. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009 Oct;68(10):1609-12. Nicolaou S, Yong-Hing CJ, Galea-Soler S, Hou DJ, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. AJR Am J Roentgenol. 2010 Apr;194(4):1072-8. Ko KH, Hsu YC, Lee HS, Lee CH, Huang GS. Tophaceous gout of the knee: revisiting MRI patterns in 30 patients. J Clin Rheumatol. 2010 Aug;16(5):209-14. Disclosure of Interest None Declared